Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib with cisplatin plus radiotherapy in unresected stage III/IV head and neck squamous cell carcinoma
2004-000358-21Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gefitinib in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Local disease control (progression-free) rate at 2 years. Started Aug 2004; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2004-000358-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000358-21.